Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
NCT ID: NCT01025934
Last Updated: 2009-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
NCT01854593
Intravitreal Bevacizumab for Diabetic Retinopathy
NCT00600262
Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT01389505
Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy
NCT00347698
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage
NCT01091896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
7 days
Bevacizumab
20 days
Bevacizumab
sham
sham
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
sham
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* tractional retinal detachment
* active proliferative diabetic retinopathy.
Exclusion Criteria
* cataract
* combined traction and rhegmatogenous RD
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Napoli CTO Hospital
UNKNOWN
University of Campania Luigi Vanvitelli
OTHER
References
Explore related publications, articles, or registry entries linked to this study.
di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. doi: 10.1007/s00417-010-1303-3. Epub 2010 Feb 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVBDRNA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.